4//SEC Filing
MERCK SHARP & DOHME LLC 4
Accession 0000950170-24-029165
CIK 0001708493operating
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 3:27 PM ET
Size
8.4 KB
Accession
0000950170-24-029165
Insider Transaction Report
Form 4
MERCK SHARP & DOHME CORP.
10% Owner
Transactions
- Purchase
Common Stock, par value $0.0001
2024-03-11$23.00/sh+21,397,205$492,135,715→ 1,000 total(indirect: See Footnote)
Merck & Co., Inc.
10% Owner
Transactions
- Purchase
Common Stock, par value $0.0001
2024-03-11$23.00/sh+21,397,205$492,135,715→ 1,000 total(indirect: See Footnote)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger, dated as of January 7, 2024 by and among Merck Sharp & Dohme LLC, a wholly owned subsidiary of Merck & Co. Inc. ("Parent"), Hawaii Merger Sub, Inc., a wholly owned subsidiary of Merck Sharp & Dohme LLC ("Merger Sub"), and Harpoon Therapeutics, Inc. ("Harpoon"), Merger Sub merged with and into Harpoon (the "Merger") on March 11, 2024. Upon completion of the Merger, each share of common stock of Harpoon that was issued and outstanding immediately prior to the effective time of the Merger was cancelled, and each share of common stock of Merger Sub was converted into one share of common stock of the surviving corporation.
- [F2](Continued from footnote 1) Consequently, upon the consummation of the Merger on March 11, 2024, Parent became the direct beneficial owner of 1,000 shares of common stock of the surviving corporation, representing 100% of the issued and outstanding shares of common stock of the surviving corporation. Merck & Co., Inc. is the indirect beneficial owner of such shares.
Documents
Issuer
Harpoon Therapeutics, Inc.
CIK 0001708493
Entity typeoperating
IncorporatedNJ
Related Parties
1- filerCIK 0000064978
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 3:27 PM ET
- Size
- 8.4 KB